# Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids

> **NCT02111603** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 13 (actual)

## Conditions studied

- Diarrhea Predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** Colesevelam

## Key facts

- **NCT ID:** NCT02111603
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-08
- **Final completion:** 2015-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111603, "Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT02111603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*